BEIJING, Aug. 28, 2025 /PRNewswire/ — Noetix Robotics, a fast-growing humanoid robotics company headquartered in Beijing, achieved outstanding results at the Global Humanoid Robotics Games, earning two gold medals and one silver to place third overall on the medal table. Competing with its humanoid robots N2 and the newly launched E1 across nine categories, Noetix demonstrated both athletic excellence and technological innovation, marking a major milestone in its mission to make humanoid robots part of everyday life.

“Our success at this year’s Games reflects the progress we have made and the path we are committed to,” said Zheyuan Jiang, Chairman of Noetix Robotics. “Humanoid robots are more than an engineering breakthrough. They are a bridge between technology and human life. At Noetix, we are focused on moving robots beyond the laboratory and into everyday settings, where they can become trusted companions and assistants.”

Beijing has become a leading hub for robotics, fueled by strong policy support and steady investment in core technologies and the supply chain. The city has fostered a vibrant ecosystem of robotics companies with backing in talent, funding, and facilities. Noetix Robotics has also benefited from substantial support from the Beijing government, including talent policies, workspace, and investment incentives. By hosting the Global Humanoid Robotics Games, Beijing created a fair international stage for competition, pushing technical progress and sparking public interest in embodied intelligence. All three top medal-winning teams this year were backed by the Beijing Robotics Industry Development Fund, highlighting the city’s strategic commitment to the field.

Noetix Robotics was among the companies with the broadest participation, entering nine different events including the 100 meters, 400 meters, 1,500 meters, 4×100-meter relay, 100-meter hurdles, high jump, standing long jump, floor exercise, and solo dance. The company competed with two humanoid robots, the compact N2 and the new E1, which together showcased versatility, agility and innovation in both athletic and artistic arenas.

The N2 features 18 degrees of freedom, a lightweight design, one to two hours of battery life, and a maximum running speed of 3.2 meters per second. Powered by self-developed motion control algorithms, it can adapt to complex terrain and perform advanced movements such as flips, sprinting, and dancing. It has gained recognition for its strong performance-to-cost ratio and is widely used in education, research, and dynamic demonstrations.

The E1, an advanced bipedal humanoid, stands 1.36 meters tall with 21 degrees of freedom, extended arms, waist flexibility, and modular expansion. It walks at 1.2 meters per second with one to two hours of endurance. Powered by multi-modal AI, the E1 synchronizes speech, facial expressions, and body movements with low-latency response, enabling multilingual interaction and emotional expression. Its 48V low-power system supports memory, personality development, and immersive engagement while allowing customizable appearance and persona. With modular options such as dexterous hands and advanced arms, the E1 is one of the most versatile humanoid robots in its class.

On the field, Noetix Robotics claimed two golds and a silver, showcasing both athletic skill and cultural flair. The E1 took gold in the standing long jump with a 1.25-meter leap, while the N2 dazzled in floor exercise, scoring 41.60 points with a series of jumps and flips, higher than the combined totals of all other competitors. The silver came in solo dance, where Noetix and the Beijing Dance Academy performed Yingge, a traditional folk dance from China’s Chaozhou-Shantou region. Blending culture with technology, the routine earned 95.30 points, just 0.1 short of gold.

Looking ahead, Noetix Robotics aims to make humanoid robots part of daily life, serving as companions, helpers, and household assistants. The company plans to further enhancing their athletic and functional abilities, moving them from labs and competitions into real-world applications that enrich everyday living.

About Noetix Robotics

Founded in September 2023 in Beijing, Noetix Robotics focuses on developing and manufacturing humanoid robots. The company has built proprietary servo motors and motion control algorithms that enable highly integrated and intelligent systems. Its technologies power fast bipedal running, natural interaction, and advanced manipulation. Noetix is committed to creating the next generation of humanoid robots for household services, eldercare, education, companionship, and research, with the mission of making robots a practical part of daily life.

BERLIN, Aug. 28, 2025 /PRNewswire/ — viaim, an AI hardware innovator specializing in intelligent, human-centered products, today announced it will showcase its new OpenNote Earbuds at IFA 2025, where they will make their first appearance on the world stage as a lifestyle productivity device that combines premium design, all-day comfort, and powerful AI features.

With this upcoming showcase, OpenNote introduces a new category of Lifestyle Productivity Earbuds, designed for professionals and creatives who want to stay connected, capture inspiration, and manage tasks throughout the day. Unlike traditional earbuds focused only on noise cancellation or sports, OpenNote combines style, comfort, and intelligent AI functions. Users can record ideas instantly, transcribe conversations in real time, and generate summaries and task lists automatically, all while enjoying a lightweight open-ear design that supports seamless transitions between work and leisure.

The upcoming presentation will also represent the completion of viaim’s AI audio ecosystem. Following the CES introductions of RecDot, professional-grade AI recording earphones, and NoteKit, a portable transcription system, OpenNote brings the lifestyle element that connects professional, computer-based, and mobile everyday scenarios. Together these products give users a complete set of tools to manage work and life with more freedom and efficiency.

OpenNote’s design uses aerospace-grade memory titanium and liquid silicone to deliver a secure and comfortable fit, with an open-ear hook that allows users to stay aware of their surroundings. This makes it especially suitable for long wear, glasses users, fitness activities, and professional environments where awareness is important. It reflects viaim’s belief that productivity should never come at the expense of comfort or connection to the world.

At IFA, OpenNote will be showcased with enhanced AI capabilities, including instant recording, real-time transcription, smarter summaries, to-do generation, mind map visualization, and live translation. It also offers all-day endurance and delivers premium, high-resolution sound in a sleek design.

“OpenNote is our bridge between productivity and lifestyle,” said Shawn Ma, CEO of viaim. “It helps people stay creative, connected, and comfortable in every moment.”

OpenNote will be featured at ShowStoppers Media Day (Booth #67) and viaim’s main booth in Hall H11.2, Stand 107 at IFA Berlin 2025, where visitors will be among the first to experience how it transforms busy, multilingual meetings into clear, actionable insights. The OpenNote is available now on Amazon for $219.

For more information, please visit www.viaim.ai.

About viaim

viaim is an innovative consumer electronics brand merging intelligent technology with human-centered design. From AI-powered productivity tools to premium lifestyle audio, viaim creates products that help people connect, create, and perform — anywhere life takes them.

CYBERJAYA, Malaysia, Aug. 28, 2025 /PRNewswire/ — Futurise Sdn Bhd (Futurise), in collaboration with the Medical Device Authority (MDA), hosted the latest edition of RegTalk at the Siemens Healthineers Experience Center, focusing on “AI Medical Devices in Malaysia – Balancing Innovation & Safety.”

The session brought together regulators, industry leaders, and policy experts to explore the opportunities and challenges of artificial intelligence in healthcare. The discussion highlighted the critical balance between fostering innovation and ensuring patient safety, clinical validation and ethical data use.

Shafinaz Salim, Acting CEO of Futurise, delivered the welcome address, underscoring Malaysia’s pivotal moment in digital health.  “The convergence of AI and medical technology presents extraordinary opportunities from predictive diagnostics to real-time patient monitoring. Yet, these advancements also introduce new complexities that must be navigated carefully especially when it comes to public safety, clinical validation, and ethical data use,” said Shafinaz.

She also announced plans to collaborate with MDA in establishing Malaysia’s first regulatory sandbox for medical devices. “This proposed regulatory sandbox is more than a testing mechanism. It is a strategic platform to accelerate responsible innovation, by allowing innovators to safely trial AI-driven medical technologies within a controlled environment under the oversight of MDA. Our aim is clear and that is to support industry growth while safeguarding public health, in full alignment with MDA’s mandate,” she added.

Shafinaz further emphasised the importance of enabling innovation through progressive regulatory frameworks. “To achieve this vision, we must address a crucial challenge: regulation. Innovation thrives in environments that allow experimentation, and this is where regulatory sandboxes can play a transformative role. The sandbox framework allows industries to experiment with new ideas without the immediate constraints of existing regulations, enabling rapid prototyping and faster scaling. As Futurise is mandated by the Government to drive the National Regulatory Sandbox, we believe the regulatory sandbox is the perfect enabler and plays a crucial role in this.”

A regulatory sandbox for medical devices would allow Malaysia to pilot and validate AI-driven medical technologies in a risk-managed environment, enable regulatory bodies to observe and respond to real-time challenges, build confidence among innovators, clinicians, and the public, and ultimately fast-track the adoption of safe, patient-centric innovations into the healthcare ecosystem.

The keynote was delivered by Aidahwaty M. Olaybal, Senior Director of the Pre-Market Control Division, Medical Device Authority (MDA), who emphasised the importance of regulatory frameworks in ensuring innovation is aligned with patient safety and trust. She highlighted that as AI-driven technologies continue to evolve, regulatory oversight must remain adaptive and forward-looking to address emerging risks. Aidahwaty also stressed that collaboration between regulators, industry, and healthcare professionals is essential to build a resilient ecosystem that balances innovation with public confidence. 

“Striking the right balance between innovation and safety requires centring collaboration, bringing together developers, clinicians, ethicists, and regulators in a shared space of co-creation. It also demands rigorous real-world validation, beyond lab environments, to ensure AI devices perform reliably in diverse clinical settings. Regulatory sandboxes offer the ideal environment to test and iterate safely. And importantly, education must remain continuous for developers, users, and decision-makers alike, so that we evolve alongside our technology,” said Aidahwaty.

The panel discussion was moderated by Deepak Pillai, Partner at Christopher & Lee Ong Malaysia, and featured Idamazura Idris @ Harun, Senior Director of the Policy and Strategic Planning Division at the Medical Device Authority (MDA), Dr. Ylu-Cho Chung, Head of Research Collaboration at Siemens Healthcare Singapore, and Ella Al-Hakim, Associate at Asia Group Advisors.

The panel explored key issues such as regulatory harmonisation, international best practices, ethical considerations in AI deployment, and strategies to accelerate the adoption of AI-powered medical devices responsibly.

The event reaffirmed the importance of public-private collaboration to ensure Malaysia strengthens its position as a leader in digital health innovation, while maintaining the highest standards of safety and trust.

Looking ahead, Futurise highlighted that building an enabling ecosystem will require active participation from stakeholders across the healthcare value chain including regulators, clinicians, innovators, investors, and patients. By fostering open dialogue, knowledge-sharing, and capacity-building, Malaysia can establish a strong foundation for AI-driven medical technologies to thrive. 

Futurise remains committed to advancing a safe and progressive digital health ecosystem. By working hand-in-hand with government and industry partners, the organisation aims to shape a regulatory landscape that not only empowers businesses and drives innovation, but also positions Malaysia as a leader in global digital health and industrial growth.

As Futurise and MDA move forward with the development of the regulatory sandbox framework, the priority will be to align innovation with patient-centric outcomes, ensuring that Malaysia’s healthcare system remains both progressive and trustworthy in the age of artificial intelligence. This outcome of RegTalk 2025 sets the stage for a broader roadmap where regulatory sandboxes will serve as a key mechanism to test and refine breakthrough innovations in a structured environment, supporting Malaysia’s ambitions in digital health while contributing to ASEAN’s collective effort in shaping safe and sustainable healthcare solutions powered by technology.

For more information, please visit www.futurise.com.my.

About Futurise

Futurise is a wholly-owned subsidiary of Cyberview Sdn Bhd under the Ministry of Finance. It is mandated by the Government of Malaysia to manage the National Regulatory Sandbox, providing public policy advisory and acting as a key enabler of regulatory solutions to expedite innovation and future-proof Malaysia’s economy.

About Medical Device Authority (MDA)

MDA is the government agency entrusted to serve the Malaysia medical device industry. It is a federal statutory agency under the Ministry of Health Malaysia to implement and enforce the Medical Device Act 2012 (Act 737). The main objectives of the Act are to address public health and safety issues related to medical devices and to facilitate medical device trade and industry.

Follow Futurise social media for updates:

FB: https://www.facebook.com/futurisemy/
Instagram: https://www.instagram.com/futurisemy
Linkedin: https://www.linkedin.com/company/futurise/
Twitter: https://twitter.com/FuturiseMY